Selinexor for Heavily Pretreated RRRMM

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Phase 2 data may support atezolizumab plus chemotherapy as a treatment option in advanced or recurrent thymic carcinoma.

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Kathleen N. Moore, MD, MS

March 17th 2025

FDA Approves PET Imaging Agent for Prostate Cancer

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

The new drug application for TLX007-CDx has been approved by the FDA for patients with prostate cancer.

Aditya Bardia, MD, MPH;Ritu Salani, MD;Scarlett Lin Gomez, PhD;Marwan G. Fakih, MD;Elizabeth Ren Zhang-Velten, MD, PhD;Frances Chow, MD;James B. Yu, MD, MHS, FASTRO

March 10th 2025

Durvalumab Does Not Surpass Cetuximab in Head and Neck Cancer

Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.

Data Show Guideline-Concordant Care Gaps in Inflammatory Breast Cancer

Christina Henson, MD, discusses recent phase 3 trial results comparing durvalumab to cetuximab in head and neck cancer, and why the trial was stopped early.

Timely guideline-concordant care may mitigate racial and ethnic disparities in overall survival among patients with inflammatory breast cancer.

Atezolizumab/Chemotherapy May Show Meaningful Activity in Thymic Carcinoma

Timely guideline-concordant care may mitigate racial and ethnic disparities in overall survival among patients with inflammatory breast cancer.

Related Content

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Phase 2 data may support atezolizumab plus chemotherapy as a treatment option in advanced or recurrent thymic carcinoma.

Kathleen N. Moore, MD, MS

March 17th 2025

FDA Approves PET Imaging Agent for Prostate Cancer

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

The new drug application for TLX007-CDx has been approved by the FDA for patients with prostate cancer.

Aditya Bardia, MD, MPH;Ritu Salani, MD;Scarlett Lin Gomez, PhD;Marwan G. Fakih, MD;Elizabeth Ren Zhang-Velten, MD, PhD;Frances Chow, MD;James B. Yu, MD, MHS, FASTRO

March 10th 2025

Durvalumab Does Not Surpass Cetuximab in Head and Neck Cancer

Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.

Data Show Guideline-Concordant Care Gaps in Inflammatory Breast Cancer

Christina Henson, MD, discusses recent phase 3 trial results comparing durvalumab to cetuximab in head and neck cancer, and why the trial was stopped early.